Summary
The effects of somatostatin and a long acting, glucagon selective somatostatin analog (des-Ala1Gly2[His4,5-D-Trp8]-somatostatin), were studied during arginine tolerance tests in normal anaesthetized rats. Arginine infusion in control animals resulted in a rapid increase in plasma insulin and glucagon, and an increase of 15±5 mg/dl in plasma glucose. Somatostatin infusion (1 mg/kg/h) resulted in suppression of basal insulin secretion and a decrease in arginine-induced insulin and glucagon release. Glucose levels increased rapidly during the combined arginine-somatostatin infusion reaching a peak of 72±10 mg/dl above basal levels. Similar results were obtained when somatostatin was injected SC (1 mg/kg) at times 0, 15, 30, and 45 minutes (arginine infused from 30–60 minutes). A single injection (1 mg/kg) of the long-acting somatostatin analogue resulted in significant inhibition of basal insulin and glucagon release; during arginine infusion glucagon levels rose only slightly, the insulin response was, however, nearly normal, and only a small arginine-induced increase in glucose levels was observed. Carbohydrate absorption was not influenced by either somatostatin or the analogue.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Reference
Alberti, K. G. M. M., Christensen, N. J., Christensen, S. E., Hansen, Aa. P., Iversen, J., Lundbaek, K., Seyer-Hansen, K., Ørskov, H.: Inhibition of insulin secretion by somatostatin. Lancet1973 II, 1299–1301
Gerich, J. E., Lorenzi, M., Schneider, J., Kwan, C. W., Karam, J. H., Guillemin, R., Forsham, P. H.: Inhibition of pancreatic glucagon responses to arginine by somatostatin in normal man and insulin-dependent diabetics. Diabetes23, 876–880 (1974)
Guillemin, R., Gerich, J. E.: Somatostatin: physiological and clinical significance. Annu. Rev. Med.27, 379–388 (1976)
Lins, P. E., Efendic, S.: Hyperglycemia induced by somatostatin in normal subjects. Horm. Metab. Res.8, 497–498 (1976)
Sherwin, R. S., Hendler, R., DeFronzo, R., Wahren, J., Felig, P.: sulin secretion by somatostatin. Proc. Natl. Acad. Sci. USA74, 348–352 (1977)
Tamborlane, W. V., Sherwin, R. S., Hendler, R., Felig, P.: Metabolic effects of somatostatin in maturity-onset diabetics. N. Engl. J. Med.297, 181–183 (1977)
Leblanc, H., Anderson, J. R., Sigel, M. B., and Yen, S. S. C.: Inhibitory action of somatostatin on pancreaticα andβ cell function. J. Clin. Endocrinol. Metab.40, 568–572 (1975)
Waldhäusl, W., Bratusch-Marrain, P., Dudczak, R., Deutsch, E.: The diabetogenic action of somatostatin in healthy subjects and in maturity onset diabetics. J. Clin. Endocrinol. Metab.44, 876–883 (1977)
Bratusch-Marrain, P., Björkman, O., Hagenfeldt, L., Waldhäusl, W., Wahren, J.: Influence of arginine on splanchnic glucose metabolism in man. Diabetes28, 126–131 (1979)
Brown, M., Rivier, J., Vale, W.: Somatostatin: analogs with selected biological activities. Science196, 1467–1469 (1977)
Lien, E. L.: Effect of somatostatin and a glucagon-specific analog on glucose homeostasis during arginine infusion. Metabolism27, 1095–1100 (1978)
Sarantakis, D., Teichman, J., Fenichel, R., Lien, E.: [des-Ala1, Gly2]-His4,5D-Trp8-somatostatin. A glucagon-specific and longacting somatostatin analog. FEBS Lett.92, 153–155 (1978)
Hales, C. N., Randle, P. J.: Immunoassay of insulin with insulin antibody recipitate. Biochem. J.88, 137–148 (1963)
Faloona, G. R., Unger, R. H.: Glucagon. In: Methods of hormone radioimmunoassay. Jaffe, B. M., Behrman, H. R. (eds.), pp 317–330. New York: Academic Press 1974
Brazeau, P., Rivier, J., Vale, W., Guillemin, R.: Inhibition of growth hormone secretion in the rat by synthetic somatostatin. Endocrinology94, 184–187 (1974)
Leblanc, H., Rigg, L., Yen, S.: The response of pancreatic and pituitary hormones to pulse and constant infusion of somatostatin. J. Clin. Endocrinol. Metab.41, 1105–1109 (1975)
Salter, J. M., Eyrin, C., Laidlaw, J. C., Gornall, A. G.: Metabolic effects of glucagon in human subjects. Metabolism9, 753–768 (1960)
Lichtenstein, B., Winne, D.: The influence of blood flow on the absorption of 3-0-methyl glucose from the jejunum of the rat. Naunyn Schmiedebergs Arch. Pharmacol.279, 153–172 (1973)
Alvarado, F., Crane, R. K.: Phlorizin as a competitive inhibitor of the active transport of sugars by hamster small intestine,in vitro. Biochim. Biophys. Acta56, 170–172 (1962)
Unger, R. H., Aguilar-Parada, E., Muller, W. A., Eisentraut, A. M.: Studies of pancreatic alpha cell function in normal and diabetic subjects. J. Clin. Invest.49, 837–848 (1970)
Aydin, I., Raskin, P., Unger, R. H.: The effect of short-term intravenous insulin administration on the glucagon response to a carbohydrate meal in adult onset and juvenile type diabetes. Diabetologia13, 629–636 (1977)
Ohneda, A., Ishii, S., Horigome, K., Yamagata, S.: Glucagon response to arginine after treatment of diabetes mellitus. Diabetes24, 811–819 (1975)
Ludvigsson, L., Heding, L. G.: C-peptide in children with juvenile diabetes. A preliminary report. Diabetologia12, 627–630 (1976)
Grajwer, L. A., Pildes, R. S., Horwitz, D. L., Rubenstein, A. H.: Control of juvenile diabetes mellitus and its relationship to endogenous insulin secretion as measured by C-peptide immunoreactivity. J. Pediatr.90, 42–48 (1977)
Shima, K., Tanaka, R., Morishita, S., Tarui, S., Kamahara, Y., Nishikawa, M.: Studies on the etiology of “brittle diabetes”. Relationship between diabetic instability and insulinogenic reserve. Diabetes26, 717–725 (1977)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lien, E., Sarantakis, D. Effect of a long acting glucagon selective somatostatin analogue on plasma glucose, insulin and glucagon levels in the anaesthetized rat during arginine infusion. Diabetologia 17, 59–64 (1979). https://doi.org/10.1007/BF01222979
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF01222979